Foreign, feral honeybees are crowding out native bee species in southern California
Europeans introduced western honeybees (Apis mellifera L.) to the Americas in the early 1600s. They play an essential role in pollinating crops and flowering plants, and are often hailed as the "unsung heroes of our planet." They are both omnivorous and omnipresent: Researchers have found that western honeybees visit more plant species than any other species of pollinator and are the most common visitor to plants in non-managed habitats worldwide, accounting for nearly 13% of all floral visitors.
The problem is that this dominance may be coming at the cost of some native pollinators.
That's what caught the attention of Joshua Kohn, a former biology professor at UC San Diego. "Pollination biologists in general in North America tend to ignore western honeybees because they're not native," he said. "But when I saw just how abundant they were, I thought to myself: They're not just a nuisance, they're the story."
In San Diego County - a global bee biodiversity hotspot - feral honeybee populations have quietly exploded in number since the late 1960s. Many of these bees trace their ancestry to a hybrid of European and African subspecies, the latter known for traits that boost survival in hot, dry climates - places with mild winters and vegetation that blooms year-round. In other words, perfect for Southern California, where previously domesticated populations became feral colonies that thrived independent of human management, nesting in rock crevices, abandoned rodent burrows and other natural cavities.
However, despite their population growth and spread, researchers don't know much about these bees' pollen consumption, or the extent to which their foraging habits may be displacing native species.
A new study published July 7 in the journal Insect Conservation and Diversity seeks to address that knowledge gap. Drawing from field surveys in San Diego's coastal scrubland, researchers at UC San Diego found that feral honeybees - non-native, unmanaged descendants of domesticated bees - may be monopolizing local ecosystems and effectively squeezing out native pollinators such as bumblebees. In total, these feral bees now comprise about 90% of all bees in the area, according to the study.
"It's like going to the Amazon rainforest to bird-watch and seeing only pigeons," said James Hung, an ecologist at the University of Oklahoma and co-author of the study. "I was shocked. This was supposed to be a biodiversity hotspot - but all we were seeing were honeybees."
The team also wanted to understand how honeybee foraging affected pollen availability for native species, and what that might mean for the latter's ability to reproduce successfully. The researchers looked at how honeybees interacted with three native plants: black sage, white sage and distant phacelia. They found that in just two visits, a western honeybee could remove more than 60% of the pollen from these flowers. By the end of a single day for all three plant species analyzed, more than 80% of all pollen was gone.
The problem is that this leaves almost no pollen for native bees.
Kohn, a co-author of the study, explained that while western honeybees are prolific foragers, they aren't always the most effective pollinators. His previous research suggests plants pollinated by these bees often produce less fit offspring, in part due to inbreeding. This is because western honeybees tend to visit many flowers on the same plant before moving on - a behavior that increases the risk of self-fertilization.
What this means for the broader plant community is still unclear, Kohn said. "But it's likely that the offspring of plants would be more fit if they were pollinated by native pollinators. It's possible that if honeybees were not in the system that there'd be more bumblebees, which visit flowering plants much more methodically."
Kohn emphasized that the findings aren't an argument against honeybee conservation, especially given their importance to agriculture. However, they do suggest we may need to reconsider how to manage domesticated western honeybee populations.
When used for agricultural pollination, managed honeybees are often brought into an area temporarily in what's called a mobile apiary: essentially, dozens or hundreds of hives kept on a trailer or platform, moved from place to place, wherever pollination is needed. While this is essential for crops, stripping nectaring plants of resources before native species have a chance to feed could lead to their decimation.
Hung suggested designating specific forage zones for commercial beekeeping - ideally in areas less vulnerable to ecological disruption - as a way to offset that pressure. "If we can identify ecosystems that are less sensitive to disturbance - those with a lower number of endemic plant or pollinator species - we could scatter seed mixes and produce way more flowers than any comparable habitat nearby," he said. "Then, we could set aside some acres of land for beekeepers to come and park their bees and let them forage in a way that does not disrupt the native ecosystem. This would address the conflict between large-scale managed honeybee populations and the wild bees that they could potentially be impacting."
Rather than replacing crop pollination, the idea would be to offer alternative foraging options that keep honeybees from spilling into and dominating natural areas.
Longer-term, Hung said scientists may need to consider more direct forms of intervention, such as relocation or eradication. "Honeybees have dug their roots very deep into our ecosystem, so removing them is going to be a big challenge," he said. But at some point, he believes, it may be necessary to protect native plants and pollinators.
In the words of Scott Black, director of the Xerces Society for Invertebrate Conservation, "Keeping honeybees to 'save the bees' is like raising chickens to save birds."
Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP3445407, which covers its GPC3-targeted CAR-T cell therapy. On July 3, 2025, a U.S.-based biotechnology — the sole appellant among the original two opponents — formally withdrew its appeal against the EPO Opposition Division's earlier decision to maintain the patent. This withdrawal renders the EPO's decision final and binding for the opponents, effectively concluding their part in the opposition process. The patent was granted by the EPO in 2022 and opposed by two parties in 2023. Following oral proceedings, the EPO Opposition Division issued a decision to maintain the patent in amended form, upholding key claims related to the use of GPC3 CAR-T cell therapy following cyclophosphamide and fludarabine lymphodepletion pretreatment, in the treatment of liver cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, and thyroid cancer. Following the decision, only one opponent filed an appeal within the allowable period. That appeal has now been withdrawn. Under EPO procedures, the opponents or any other third party can no longer challenge the patent at the EPO. This development further reinforces CARsgen's intellectual property position in the field of GPC3-targeted CAR-T therapies, a promising and innovative approach for the treatment of solid tumors. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics

Associated Press
6 hours ago
- Associated Press
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP3445407, which covers its GPC3-targeted CAR-T cell therapy. On July 3, 2025, a U.S.-based biotechnology — the sole appellant among the original two opponents — formally withdrew its appeal against the EPO Opposition Division's earlier decision to maintain the patent. This withdrawal renders the EPO's decision final and binding for the opponents, effectively concluding their part in the opposition process. The patent was granted by the EPO in 2022 and opposed by two parties in 2023. Following oral proceedings, the EPO Opposition Division issued a decision to maintain the patent in amended form, upholding key claims related to the use of GPC3 CAR-T cell therapy following cyclophosphamide and fludarabine lymphodepletion pretreatment, in the treatment of liver cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, and thyroid cancer. Following the decision, only one opponent filed an appeal within the allowable period. That appeal has now been withdrawn. Under EPO procedures, the opponents or any other third party can no longer challenge the patent at the EPO. This development further reinforces CARsgen's intellectual property position in the field of GPC3-targeted CAR-T therapies, a promising and innovative approach for the treatment of solid tumors. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading 'Principal Risks and Uncertainties' in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics


Boston Globe
a day ago
- Boston Globe
US aid cuts halt HIV vaccine research in South Africa, with global impact
But the $46 million from the U.S. for the project was disappearing, part of the dismantling of foreign aid by the world's biggest donor earlier this year as President Donald Trump announced a focus on priorities at home. Advertisement South Africa hit hard by aid cuts South Africa has been hit especially hard because of Trump's baseless claims about the targeting of the country's white Afrikaner minority. The country had been receiving about $400 million a year via USAID and the HIV-focused PEPFAR. Now that's gone. Glenda Grey, who heads the Brilliant program, said the African continent has been vital to the development of HIV medication, and the U.S. cuts threaten its capability to do such work in the future. Significant advances have included clinical trials for lenacapavir, the world's only twice-a-year shot to prevent HIV, recently approved for use by the U.S. Food and Drug Administration. One study to show its efficacy involved young South Africans. 'We do the trials better, faster and cheaper than anywhere else in the world, and so without South Africa as part of these programs, the world, in my opinion, is much poorer,' Gray said. Advertisement She noted that during the urgency of the COVID-19 pandemic, South Africa played a crucial role by testing the Johnson & Johnson and Novavax vaccines, and South African scientists' genomic surveillance led to the identification of an important variant. Labs empty and thousands are laid off A team of researchers at the University of the Witwatersrand has been part of the unit developing the HIV vaccines for the trials. Inside the Wits laboratory, technician Nozipho Mlotshwa was among the young people in white gowns working on samples, but she may soon be out of a job. Her position is grant-funded. She uses her salary to support her family and fund her studies in a country where youth unemployment hovers around 46%. 'It's very sad and devastating, honestly,' she said of the U.S. cuts and overall uncertainty. 'We'll also miss out collaborating with other scientists across the continent.' Professor Abdullah Ely leads the team of researchers. He said the work had promising results indicating that the vaccines were producing an immune response. But now that momentum, he said, has 'all kind of had to come to a halt.' The BRILLIANT program is scrambling to find money to save the project. The purchase of key equipment has stopped. South Africa's health department says about 100 researchers for that program and others related to HIV have been laid off. Funding for postdoctoral students involved in experiments for the projects is at risk. South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research funding over the next five years due to the aid cuts, which affect not only work on HIV but also tuberculosis — another disease with a high number of cases in the country. Advertisement Less money, and less data on what's affected South Africa's government has said it will be very difficult to find funding to replace the U.S. support. And now the number of HIV infections will grow. Medication is more difficult to obtain. At least 8,000 health workers in South Africa's HIV program have already been laid off, the government has said. Also gone are the data collectors who tracked patients and their care, as well as HIV counselors who could reach vulnerable patients in rural communities. For researchers, Universities South Africa, an umbrella body, has applied to the national treasury for over $110 million for projects at some of the largest schools. During a visit to South Africa in June, UNAIDS executive director Winnie Byanyima was well aware of the stakes, and the lives at risk, as research and health care struggle in South Africa and across Africa at large. Other countries that were highly dependent on U.S. funding including Zambia, Nigeria, Burundi and Ivory Coast are already increasing their own resources, she said. 'But let's be clear, what they are putting down will not be funding in the same way that the American resources were funding,' Byanyima said. Associated Press writer Michelle Gumede in Johannesburg contributed to this report.